Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.

Abstract

AIM:

We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS).

PATIENTS AND METHODS:

Thirty-eight PCOS patients with hyperlipidemia and impaired glucose tolerance, who were followed at Department of Endocrinology and Metabolism out-patient clinic of Cerrahpasa Medical School were included in the study. Twenty patients had lifestyle changes and metformin (2000 mg/day) therapy (M group) and 18 had statin (rosuvastatin 10 mg/day) in addition to this therapy (MR group). Total and free testosterone, DHEAS, FSH, LH, estrodiol, fasting glucose, insulin, and high-sensitivity C-reactive protein (hs-CRP) levels, lipid parameters and homeostasis model assesment index (HOMAIR) were evaluated for each patient before and 12 weeks after the treatment.

RESULTS:

After 12 weeks of treatment body mass index (BMI), insulin and glucose levels, HOMA-IR had similar decreaments in both groups, whereas there was a greater decline of the total and free testosterone levels in MR group (p<0.001, p=0.004, respectively). DHEAS levels did not change in M group, however, significantly decreased in MR group after treatment (p=0.8, p=0.002, respectively). As expected hsCRP, triglyceride, total and LDL-cholesterol levels decreased more in MR group.

CONCLUSION:

Metformin and rosuvastatin combination therapy could lead to a better reduction on hyperandrogenism and on atherosclerosis-related factors in PCOS, in addition to improving lipid parameters.

• Authors: O Celik, O Acbay
• Journal: Journal of endocrinological investigation (J Endocrinol Invest) Vol. 35 Issue 10 Pg. 905-10 (Nov 2012) ISSN: 1720-8386 [Electronic] Italy
• PMID: 22522778 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Blood Glucose
• Drug Combinations
• Fluorobenzenes
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypoglycemic Agents
• Pyrimidines
• Sulfonamides
• Testosterone
• Rosuvastatin Calcium
• Metformin

Topics

• Adult
• Blood Glucose (metabolism)
• Body Mass Index
• Drug Combinations
• Female
• Fluorobenzenes (therapeutic use)
• Follow-Up Studies
• Glucose Intolerance (drug therapy, etiology)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hyperandrogenism (drug therapy, etiology)
• Hyperlipidemias (drug therapy, etiology)
• Hypoglycemic Agents (therapeutic use)
• Metformin (therapeutic use)
• Polycystic Ovary Syndrome (complications, drug therapy)
• Prognosis
• Pyrimidines (therapeutic use)
• Rosuvastatin Calcium
• Sulfonamides (therapeutic use)
• Testosterone (blood)